A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
LUNET-2
Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)
1 other identifier
observational
117
1 country
7
Brief Summary
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2023
Shorter than P25 for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 29, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 29, 2023
CompletedFirst Submitted
Initial submission to the registry
June 12, 2026
CompletedFirst Posted
Study publicly available on registry
June 17, 2026
CompletedJune 17, 2026
June 1, 2026
6 months
June 12, 2026
June 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (8)
Baseline Demographics
Baseline
Number of Patients by Tumor Status
Baseline
Duration Between Initial Diagnosis and Initiation of Primary PRRT
Baseline
Number of Patients by PRRT Line of Therapy
Approximately 1 year
Number of Patients by Type of PRRT Received
Approximately 1 year
PRRT Dosage
Approximately 1 year
Number of Patients by Treatment Interval
Approximately 1 year
Number of Patients by Co-medication
Approximately 1 year
Study Arms (1)
PRRT Cohort
Adult GEP-NET patients who received PRRT in German routine care.
Eligibility Criteria
Adult GEP-NET patients in Germany who received their first cycle of primary PRRT between 01 July 2020 and 30 June 2021.
You may qualify if:
- Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin \[CUP\], any Grade).
- Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.
You may not qualify if:
- Received a combination of PRRT with chemotherapy.
- Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Rostock, Germany
Novartis Investigative Site
Stuttgart, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Würzburg, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 12, 2026
First Posted
June 17, 2026
Study Start
April 3, 2023
Primary Completion
September 29, 2023
Study Completion
September 29, 2023
Last Updated
June 17, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share